FDA-cleared profile

Lunit INSIGHT DBT v1.1

Lunit Inc.

Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems.
FDA source Exact FDA submission Checked 2026-09-08
Intended users
Physicians interpreting screening mammograms.
FDA source Exact FDA submission Checked 2026-09-08
Care setting and population
The screening population described in the FDA intended use; the institutional care setting requires local confirmation.
Public source Exact FDA submission Checked 2026-08-31

Conservative normalization of explicit wording in an exact-submission source.

Workflow role
Concurrent detection and characterization reading aid (CADe/x), not a replacement for physician review.
FDA source Exact FDA submission Checked 2026-09-08
Required input
Screening mammograms of the female population acquired as DBT exams from compatible DBT systems.
FDA source Exact FDA submission Checked 2026-09-08
Output and human action
Lesion type, location, lesion-level and case-level abnormality scores, and outlines/markings of regions suspected for breast cancer.
FDA source Exact FDA submission Checked 2026-09-08
Limitations
Not a replacement for complete interpreting-physician review or clinical judgment; intended for screening mammography of the female population and compatible DBT systems.
FDA source Exact FDA submission Checked 2026-09-08

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242652
FDA source Exact FDA submission Checked 2026-08-31
Modality
Mammography/DBT
FDA source Exact FDA submission Checked 2026-09-08
Anatomy
Breast
FDA source Exact FDA submission Checked 2026-09-08
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2024-10-04
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Standards-based DICOM/PACS integration was identified in the FDA submission materials; compatibility with a specific PACS, RIS, EHR, or orchestrator requires confirmation.
Public source Exact FDA submission Checked 2026-08-13

Normalized from the prior exact-submission review. Confirm interface versions and local compatibility during technical evaluation.

Deployment and data flow
On-premise
Public source Exact FDA submission Checked 2026-08-13

Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08

Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08

Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08

Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Lunit INSIGHT DBT v1.1; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
FDA K242652 packet reports standalone performance for Lunit INSIGHT DBT v1.1. AUROC was 0.931 (95% CI 0.920-0.941; p < 0.0001) against a prespecified >0.903 criterion. The packet does not provide a clinical reader study or numeric sensitivity/specificity.
FDA source Exact FDA submission Checked 2026-09-08
Reported sensitivity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Lunit INSIGHT DBT v1.1 regulatory performance study summary

Stand-Alone Performance · Population described in the exact-submission ACR model card

exact submission · Tested version: Exact product version not reported; regulatory study summarized for FDA submission K242652 · Independence not established

K242652

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08

No public price or quote for the exact K242652 configuration was established in this review.

Reimbursement and coding
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-08

No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K242652. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Public source Exact FDA submission Checked 2026-09-08

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-08Last searched
21Fields reviewed
9Source classes checked
0Unreviewed PubMed leads
1Unreviewed trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR provides bounded exact-submission catalog context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 1 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-08.

Alternatives

Related tools to compare

FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM...

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23
FDA-cleared K253796

Lunit INSIGHT DBT (V1.2)

Lunit, Inc.

Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue...

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-03-26
FDA-cleared K243341

Genius AI Detection 2.0

Hologic, Inc.

Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and...

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-07-31